Abstract Library

#3052 Unique Metastatic Patterns in Neuroendocrine Neoplasms of Different Primary Origin

Introduction: Neuroendocrine neoplasms (NEN) can originate in different organs, e.g. in the gastro-enteric tract (GE), pancreas (P) or lung (L). Despite similarities in clinical and pathological characteristics in tumors of another origin, differences also exist. This might apply to metastatic patterns as well, but only limited data is available so far.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Hermans B, Derks J, Willems A, Bilochvostenko M, Bayazit S,

Keywords: neuroendocrine neoplasms, stage IV, metastases, survival, epidemiology,

#3042 The Use of Total Parenteral Nutrition in a Series of Patients with Neuroendocrine Tumours in United Kingdom and the Netherlands

Introduction: There are controversies about the use of total parental nutrition (TPN) in patients with cancer. Currently data regarding TPN use in patients with neuroendocrine tumours (NETs) are lacking.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Clement D

Authors: Clement D, Naghibi M, Khan M, Tesselaar M, Verbeek W,

Keywords: total parenteral nutrition, short bowel syndrome, inoperable small bowel obstruction, neuroendocrine tumour,

#2977 Predicting Survival in Patients with a Neuroendocrine Tumor of the Small Intestine (SI-NET)

Introduction: SI-NET comprise the largest group of neuroendocrine tumors. Because of their heterogeneity, predicting survival has proven challenging. A nomogram (NG) to assess SI-NET disease specific survival (DSS) has been developed in 2010 by Modlin, et al. based on analysis of retrospective data from the Surveillance, Epidemiology and End Results (SEER) database.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Levy S, van Veenendaal L, Korse C, Verbeek W, Vriens M,

Keywords: SI-NET, Nomogram, Survival,

#2922 Clinicopathological Characteristics of Borderline Pulmonary Neuroendocrine Neoplasms

Introduction: According to the WHO 2015 classification pulmonary neuroendocrine neoplasms (NENs) are subdivided in carcinoids and neuroendocrine carcinoma (small cell lung carcinoma and large cell neuroendocrine carcinoma (LCNEC)), based on the presence of necrosis and mitotic index (MI). However, in some NENs a discrepancy is observed between grade of differentiation and proliferation rate.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Hermans B, Derks J, Moonen L, Habraken C, von der Thusen J,

Keywords: Borderline tumor, NET grade 3, LCNEC, atypical carcinoid, WHO-classification,

#2847 Surgical and Survival Outcomes of Early Peptide Receptor Radionuclide Therapy for Downstaging Locally Advanced or Oligometastatic Pancreatic Neuroendocrine Neoplasms

Introduction: Pancreatic neuroendocrine neoplasm (pNEN) patients often present with locally advanced or metastatic disease. The objective response rate of peptide receptor radionuclide therapy (PRRT) in pNENs is 55%. Therefore, PRRT may be a possibility for patients who are not eligible for upfront curative surgery.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Minczeles N, van Eijck C, van Gils M, van Velthuysen M, Nieveen van Dijkum E,

Keywords: neoadjuvant, peptide receptor radionuclide therapy, neuroendocrine, pancreas, surgery,